RE:RE:RE:RE:RE:Keytruda+Chemo neoadjuvant in early ER+/HER2- breast cancerperhaps Roche will wait until the patent expires in a couple of years... and then run the trial all on their lonesome... 2027 isn't it..?
Of course if ONCY can get an approval before then, then they have 13 years exclusive marketing rights... (not sure about China and SE Asia - didn't they sell those for 5 million...). Yah, but fiorst they need to run a phase III... lol... yeah, like that will every happen...
Oh boy, down and down and down we go...
With great stocks in the market being hit too, when the reversal comes, the money will head to the great companies... and poor old ONCY will just rot at around a buck 25.